NEW YORK: Pfizer Inc is in talks to merge its off-patent drugs business with Mylan NV in a stock deal, according to a source familiar with the matter. Mylan shareholders would receive a little more than 40% of the newly formed entity, with Pfizer shareholders receiving the remainder, the person ...
Read More »